Jagsonpal Pharmaceuticals Limited has informed the Exchange regarding Outcome of Board Meeting held on May 06, 2025.
JAGSNPHARM · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 8.4 pts less than Nifty Microcap 250 and 7.7 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Jagsonpal Pharmaceuticals reported strong FY25 results with revenue from operations rising about 29% to Rs. 268.72 crore (from Rs. 208.70 crore in FY24) and net profit jumping roughly 146% to Rs. 55.36 crore (from Rs. 22.46 crore). Q4 FY25 revenue stood at Rs. 58.56 crore with net profit of Rs. 6.58 crore, up about 85% year-on-year. The board recommended a final dividend of Rs. 2.5 per share (125%) on the new Rs. 2 face value, and appointed S S Kothari Mehta & Co as Internal Auditor for FY26. The company acquired Yash Pharma's India and Bhutan business for Rs. 94.01 crore in June 2024, sold its Faridabad factory for Rs. 41 crore booking a Rs. 23.36 crore exceptional gain, and executed a stock split from Rs. 5 to Rs. 2 face value effective January 8, 2025. Statutory auditor Walker Chandiok & Co LLP issued an unmodified (clean) opinion. A pending customs duty demand of Rs. 5.10 crore plus equal penalty was confirmed by authorities, which the company intends to appeal.
Strong top-line growth, a near-doubling of profit, and a 125% dividend are positive signals for shareholders, though part of the profit boost came from the one-time Faridabad factory sale. The clean audit report and the Yash Pharma acquisition expanding the dermatology and childcare portfolio are supportive, while the customs duty order remains a watch item that could weigh on sentiment if the appeal fails.